Who makes Fufang Biejia Ruangan Tablet?

Fufang Biejia Ruangan Tablet is developed by Beijing 302 Hospital.

What development phase is Fufang Biejia Ruangan Tablet in?

Fufang Biejia Ruangan Tablet is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

Fufang Biejia Ruangan Tablet

Beijing 302 Hospital · FDA-approved active Small molecule Quality 0/100

Fufang Biejia Ruangan Tablet, marketed by Beijing 302 Hospital, is a pharmaceutical product with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique position due to its specific mechanism of action, which remains undisclosed. The primary risk is the potential increase in competition post-2028, when the key patent expires.

At a glance

Generic name	Fufang Biejia Ruangan Tablet
Sponsor	Beijing 302 Hospital
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Fufang Biejia Ruangan Tablet CI brief — competitive landscape report
Fufang Biejia Ruangan Tablet updates RSS · CI watch RSS
Beijing 302 Hospital portfolio CI